Compare · HEPA vs NVO
HEPA vs NVO
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2571.5x HEPA ($71.2M).
- Over the past year, HEPA is up 0.0% and NVO is down 45.7% - HEPA leads by 45.7 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for HEPA).
- NVO has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $0.32-17.57%
- $41.01-4.51%
- Market cap
- $71.2M
- $183.15B
- 1M return
- +0.00%
- -10.44%
- 1Y return
- +0.00%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 8
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HEPA
- New insider Lopriore Chase claimed ownership of 1,250,000 shares (SEC Form 3)
- SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Hepion Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Hepion Pharmaceuticals Inc.
- Director Purcell Michael J. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)
- Executive Chairman Lopriore Vincent S bought $250,000 worth of shares (6,250,000 units at $0.04) (SEC Form 4)
- Interim CEO Stetz Gary S. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)
- Director Appajosyula Sireesh bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)
- SEC Form D filed by Hepion Pharmaceuticals Inc.
- Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care